Nothing Bundt Cakes divests nine company-owned San Diego bakeries
Dallas, US-based bakery chain Nothing Bundt Cakes has sold nine company-owned bakeries in the San Diego market to private equity firm FS Investors.
Nothing Bundt Cakes has not disclosed the terms of the agreement, which represents a key milestone in the brand's long-term growth strategy and allows it to further speed up expansion in one of its most promising regions.
FS Investors has signed a development agreement to construct 16 further bakeries in the San Diego area.
Nothing Bundt Cakes has around 700 locations in the US and Canada.
The company's Bakeries Bring the Joy offers handcrafted Bundt Cakes for pickup or delivery in a range of flavours and sizes including Bundtinis, the brand's cupcake-sized Bundt Cakes, personal-sized Bundtlets and 8-inch and 10-inch Bundt Cakes.
Nothing Bundt Cakes CEO Dolf Berle stated: "Our focus at Nothing Bundt Cakes is to accelerate growth and build upon the record that we set of over 100 new bakeries in 2024.
"Selling our San Diego company-owned bakeries to FS Investors gives them a platform from which they can build a significant number of new bakeries in this region.'
FS Investors will spearhead the regional growth of Nothing Bundt Cakes, aiming to more than double its bakery count.
Commenting on the acquisition, a spokesperson for FS Investors stated: "As owners and operators who live in the San Diego area, we are tremendously excited to add the Nothing Bundt Cakes brand to our family of companies.
"The opportunity to be owners in this fast-growing concept — with strong return-on-capital characteristics for new bakery builds — is very exciting for us. We look forward to bringing joy to the San Diego community through this award-winning product and guest experience."
"Nothing Bundt Cakes divests nine company-owned San Diego bakeries" was originally created and published by Verdict Food Service, a GlobalData owned brand.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Trends Shaping the $49.2 Billion Endoscopy Procedures Industry, 2025-2030: Includes Adjusted Forecasts and Analytics Relating to the Impact of Tariffs and Trade Turbulence
Endoscopy Procedures Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Endoscopy Procedures - Global Strategic Business Report" has been added to global market for Endoscopy Procedures was valued at US$34.3 Billion in 2024 and is projected to reach US$49.2 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Endoscopy Procedures market. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Ambu A/S, Arthrex, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. The growth in the global endoscopy procedures market is driven by several factors that span epidemiological, technological, and systemic domains. At the core is the escalating global burden of gastrointestinal and pulmonary diseases, including colorectal cancer, gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD). The aging global population, combined with rising lifestyle-related risk factors such as obesity, smoking, and dietary patterns, is increasing the prevalence of these conditions and fueling demand for both diagnostic and interventional endoscopy. Moreover, the growing acceptance of regular cancer screening in high-risk populations is reinforcing the role of colonoscopy and upper GI endoscopy as preventive crucial driver is the technological sophistication of modern endoscopy platforms, which now support image-guided therapy, AI-assisted diagnostics, and real-time histological assessment. These capabilities are shortening procedure times, improving accuracy, and reducing the need for follow-up interventions, thereby appealing to both clinicians and payers. Health systems worldwide are recognizing the cost-effectiveness of early diagnosis and minimally invasive intervention, leading to favorable reimbursement structures and procedural mandates. In parallel, the rise of outpatient and ambulatory surgical centers is expanding procedural capacity without burdening hospital the emphasis on cross-specialty endoscopic training, coupled with increasing patient preference for non-surgical alternatives, is supporting long-term procedural volume growth. Medical device manufacturers are responding by launching modular, portable, and scalable platforms suitable for diverse practice settings, including rural clinics and smaller hospitals. These strategic product innovations, alongside government-backed screening initiatives and international collaborations in clinical education, ensure that endoscopy will remain central to the future of diagnostic and therapeutic care Insights: Market Growth: Understand the significant growth trajectory of the Disposable Endoscopes segment, which is expected to reach US$35.1 Billion by 2030 with a CAGR of a 7.2%. The Reusable Endoscopes segment is also set to grow at 3.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $9.3 Billion in 2024, and China, forecasted to grow at an impressive 10% CAGR to reach $10.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Key Questions Answered: How is the Global Endoscopy Procedures Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 41 companies featured in this Endoscopy Procedures market report include: Ambu A/S Arthrex, Inc. B. Braun Melsungen AG Boston Scientific Corporation CapsoVision, Inc. Carl Zeiss AG CONMED Corporation Cook Medical Ethicon Endo-Surgery, LLC Fortimedix Surgical B.V. Fujifilm Holdings Corporation HOYA Corporation (PENTAX Medical) Intuitive Surgical, Inc. Johnson & Johnson MedTech Karl Storz SE & Co. KG Medtronic plc MicroPort Scientific Corporation Olympus Corporation Richard Wolf GmbH Stryker Corporation This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 386 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $34.3 Billion Forecasted Market Value (USD) by 2030 $49.2 Billion Compound Annual Growth Rate 6.2% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Endoscopy Procedures - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Incidence of GI, Pulmonary, and Urological Disorders Drives Demand for Endoscopy Procedures Shift Toward Early Diagnosis and Preventive Screening Throws Spotlight on Diagnostic Endoscopy Volumes Expansion of Ambulatory Surgical Centers Strengthens Business Case for High-Throughput Endoscopy Suites Technological Advancements in Flexible and Capsule Endoscopes Enhance Patient Comfort and Diagnostic Yield Investment in High-Definition and 4K Endoscopy Platforms Fuels Clinical Adoption in Complex Procedures Increased Use of AI-Assisted Polyp Detection and Lesion Characterization Drives Innovation in Procedure Efficiency Integration of Endoscopy With EHR and PACS Systems Supports Streamlined Reporting and Workflow Growth in Endoscopic Therapeutics for GI Bleeds, Obesity, and Strictures Expands Procedure Complexity Rising Colorectal Cancer Screening Initiatives by Governments Propel Growth in Colonoscopy Volume Reimbursement Approvals for Bariatric and Esophageal Endoscopic Treatments Promote Procedural Expansion Emphasis on Reprocessable, Single-Use, and Hybrid Endoscopes Enhances Infection Control Standards Global Aging Population and Rise in Comorbid Conditions Fuel Diagnostic Endoscopy Demand Surge in Pulmonary Endoscopy and Bronchoscopy Procedures With EBUS Drives Volume in Respiratory Care Growing Preference for Sedation-Free and Office-Based Endoscopy Increases Patient Throughput Emergence of AI-Powered Decision Support Tools Enhances Clinical Workflow During Procedures Expansion of Endoscopic Oncology Procedures Including EMR and ESD Expands Therapeutic Applications Public Awareness Campaigns and Screening Recommendations Spur Uptake of Endoscopic Exams Rapid Growth in Medical Tourism in Asia and Latin America Bolsters Demand for Elective Endoscopy Cross-Specialty Use in ENT, Gynecology, and Orthopedics Supports Broader Endoscopic Equipment Adoption OEM-Clinic Collaborations Drive Investment in Endoscopy Center Design and Staff Training For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Endoscopy Procedures Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
18 minutes ago
- Yahoo
Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs
Philip Morris International Inc., a leading tobacco company, is committed to becoming a 100% smoke-free entity. By March 2025, 42% of revenue was from smoke-free products like IQOS and ZYN. The firm is advancing digital transformation and tech initiatives to enhance health-focused and prescription products. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Philip Morris International Inc. - 2025" company profile has been added to offering. The report provides insights into the Philip Morris International's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Philip Morris International Inc. (Philip Morris) is a US-based multinational tobacco company. It produces cigarettes and a variety of smoke-free products, including e-vapor, heated tobacco, and oral smokeless products. Philip Morris aims to become a 100% smoke-free products company in the near future. As of March 31, 2025, smoke-free products accounted for 42% of Philip Morris' overall revenue. The company is also focusing on developing and commercializing oral and inhaled consumer health & wellness products, as well as inhaled prescription products for cardiovascular emergencies and pain management. IQOS and ZYN are the leading smoke-free brands of the company, while Marlboro, Parliament, Chesterfield, L&M and Philip Morris are the leading cigarette report provides information and insights into Philip Morris' tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives covering partnerships and product launches. Insights on each technology initiative including technology theme, objective, and benefits. Details of estimated ICT budgets. Reasons to Buy Gain insights into Philip Morris' tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and other Innovation Programs Technology Focus Technology Initiatives Venture Arm: PM Equity Partner Partnerships Network Map ICT Budget and Contracts Key Executives For more information about this company profile visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
18 minutes ago
- Yahoo
Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Amgen Inc. (NASDAQ:AMGN) does have debt on its balance sheet. But should shareholders be worried about its use of debt? This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we think about a company's use of debt, we first look at cash and debt together. You can click the graphic below for the historical numbers, but it shows that Amgen had US$57.4b of debt in March 2025, down from US$64.0b, one year before. On the flip side, it has US$8.81b in cash leading to net debt of about US$48.6b. According to the last reported balance sheet, Amgen had liabilities of US$23.0b due within 12 months, and liabilities of US$60.2b due beyond 12 months. On the other hand, it had cash of US$8.81b and US$8.13b worth of receivables due within a year. So its liabilities total US$66.2b more than the combination of its cash and short-term receivables. While this might seem like a lot, it is not so bad since Amgen has a huge market capitalization of US$156.9b, and so it could probably strengthen its balance sheet by raising capital if it needed to. However, it is still worthwhile taking a close look at its ability to pay off debt. See our latest analysis for Amgen We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio). Amgen has a debt to EBITDA ratio of 3.1 and its EBIT covered its interest expense 3.4 times. Taken together this implies that, while we wouldn't want to see debt levels rise, we think it can handle its current leverage. Fortunately, Amgen grew its EBIT by 9.9% in the last year, slowly shrinking its debt relative to earnings. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately the future profitability of the business will decide if Amgen can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts. But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. During the last three years, Amgen generated free cash flow amounting to a very robust 88% of its EBIT, more than we'd expect. That positions it well to pay down debt if desirable to do so. When it comes to the balance sheet, the standout positive for Amgen was the fact that it seems able to convert EBIT to free cash flow confidently. However, our other observations weren't so heartening. For example, its interest cover makes us a little nervous about its debt. Considering this range of data points, we think Amgen is in a good position to manage its debt levels. But a word of caution: we think debt levels are high enough to justify ongoing monitoring. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should be aware of the 1 warning sign we've spotted with Amgen . When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
